Development of vaccine for dyslipidemia targeted to a proprotein convertase subtilisin/kexin type 9 (PCSK9) epitope in mice

Impact of age and sex on the development of atherosclerosis and expression of the related genes in apoE deficient mice

(2016) Mengyang Liu et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease

(2016) Dhruv S. Kazi et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Long-Term Reduction of High Blood Pressure by Angiotensin II DNA Vaccine in Spontaneously Hypertensive RatsNovelty and Significance

(2015) Hiroshi Koriyama et al.   HYPERTENSION

PCSK9 deficiency unmasks a sex- and tissue-specific subcellular distribution of the LDL and VLDL receptors in mice

(2015) Anna Roubtsova et al.   JOURNAL OF LIPID RESEARCH

A cholesterol-lowering VLP vaccine that targets PCSK9

(2015) Erin Crossey et al.   VACCINE

Development and Applications of CRISPR-Cas9 for Genome Engineering

(2014) Patrick D. Hsu et al.   CELL

Peptide-Based Anti-PCSK9 Vaccines - An Approach for Long-Term LDLc Management

(2014) Gergana Galabova et al.   PLoS One

Therapeutic vaccine against DPP4 improves glucose metabolism in mice

(2014) Zhengda Pang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The safety of therapeutic monoclonal antibodies: Implications for cardiovascular disease and targeting the PCSK9 pathway

(2013) A.L. Catapano et al.   ATHEROSCLEROSIS

PCSK9 Inhibitors: Potential in Cardiovascular Therapeutics

(2013) Rose Q. Do et al.   Current Cardiology Reports

An Anti-PCSK9 Antibody Reduces LDL-Cholesterol On Top Of A Statin And Suppresses Hepatocyte SREBP-Regulated Genes

(2012) Liwen Zhang et al.   International Journal of Biological Sciences

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study

(2012) Michael J Koren et al.   LANCET

Atorvastatin with or without an Antibody to PCSK9 in Primary Hypercholesterolemia

(2012) Eli M. Roth et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Proprotein Convertase Subtilisin-like/Kexin Type 9 (PCSK9) C-terminal Domain Antibody Antigen-binding Fragment Inhibits PCSK9 Internalization and Restores Low Density Lipoprotein Uptake

(2010) Yan G. Ni et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

“Self-Nonself” Peptides in the Design of Vaccines

(2009) Darja Kanduc   CURRENT PHARMACEUTICAL DESIGN

Antagonism of Secreted PCSK9 Increases Low Density Lipoprotein Receptor Expression in HepG2 Cells

(2009) Markey C. McNutt et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Mutation S462P in the PCSK9 gene reduces secretion of mutant PCSK9 without affecting the autocatalytic cleavage

(2008) Jamie Cameron et al.   ATHEROSCLEROSIS

Epitopic peptides with low similarity to the host proteome: towards biological therapies without side effects

(2008) Darja Kanduc   EXPERT OPINION ON BIOLOGICAL THERAPY

Structural and Biochemical Characterization of the Wild Type PCSK9-EGF(AB) Complex and Natural Familial Hypercholesterolemia Mutants

(2008) Matthew J. Bottomley et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

PCSK9 and LDL cholesterol: unravelling the target to design the bullet

(2008) Philippe Costet et al.   TRENDS IN BIOCHEMICAL SCIENCES